Literature DB >> 11133489

Effect of acetylsalicylic acid on endogenous I kappa B kinase activity in lung epithelial cells.

C G Yoo1, S Lee, C T Lee, Y W Kim, S K Han, Y S Shim.   

Abstract

The anti-inflammatory effect of acetylsalicylic acid (ASA) has been thought to be secondary to the inhibition of prostaglandin synthesis. Because doses of ASA necessary to treat chronic inflammatory diseases are much higher than those needed to inhibit prostaglandin synthesis, a prostaglandin-independent pathway has been emerging as the new anti-inflammatory mechanism of ASA. Here, we examined the effect of ASA on the interleukin (IL)-1 beta- and tumor necrosis factor (TNF)-alpha-induced proinflammatory cytokine expression and evaluated whether this effect is closely linked to the nuclear factor (NF)-kappa B/I kappa B-alpha pathway. A high dose of ASA blocked IL-1 beta- and TNF-alpha-induced TNF-alpha and IL-8 expression, respectively. ASA inhibited TNF-alpha-induced activation of NF-kappa B by preventing phosphorylation and subsequent degradation of I kappa B-alpha in a prostanoid-independent manner. TNF-alpha-induced activation of I kappa B kinase was also suppressed by ASA pretreatment. These observations suggest that the anti-inflammatory effect of ASA in lung epithelial cells may be due to suppression of I kappa B kinase activity, which thereby inhibits subsequent phosphorylation and degradation of I kappa B-alpha, activation of NF-kappa B, and proinflammatory cytokine expression in lung epithelial cells.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11133489     DOI: 10.1152/ajplung.2001.280.1.L3

Source DB:  PubMed          Journal:  Am J Physiol Lung Cell Mol Physiol        ISSN: 1040-0605            Impact factor:   5.464


  9 in total

1.  Aspirin reduces lipopolysaccharide-induced pulmonary inflammation in human models of ARDS.

Authors:  U Hamid; A Krasnodembskaya; M Fitzgerald; M Shyamsundar; A Kissenpfennig; C Scott; E Lefrancais; M R Looney; R Verghis; J Scott; A J Simpson; J McNamee; D F McAuley; C M O'Kane
Journal:  Thorax       Date:  2017-01-12       Impact factor: 9.139

2.  Lobolide, a diterpene, blockades the NF-κB pathway and p38 and ERK MAPK activity in macrophages in vitro.

Authors:  Xiao-fen Lv; Si-han Chen; Jie Li; Jian-ping Fang; Yue-wei Guo; Kan Ding
Journal:  Acta Pharmacol Sin       Date:  2012-08-27       Impact factor: 6.150

3.  Acetylsalicylic acid inhibits IL-18-induced cardiac fibroblast migration through the induction of RECK.

Authors:  Jalahalli M Siddesha; Anthony J Valente; Siva S V P Sakamuri; Jason D Gardner; Patrice Delafontaine; Makoto Noda; Bysani Chandrasekar
Journal:  J Cell Physiol       Date:  2014-07       Impact factor: 6.384

4.  Appetite for destruction: E3 ubiquitin-ligase protection in cardiac disease.

Authors:  Monte S Willis; Jonathan C Schisler; Cam Patterson
Journal:  Future Cardiol       Date:  2008-01

Review 5.  NSAIDs: learning new tricks from old drugs.

Authors:  Federico Díaz-González; Francisco Sánchez-Madrid
Journal:  Eur J Immunol       Date:  2015-01-21       Impact factor: 5.532

6.  Caspase-1 inhibition attenuates activation of BV2 microglia induced by LPS-treated RAW264.7 macrophages.

Authors:  Yang Pan; Bo Shen; Qin Gao; Jun Zhu; Jingde Dong; Li Zhang; Yingdong Zhang
Journal:  J Biomed Res       Date:  2016-04-15

Review 7.  Overview of First-Line and Second-Line Pharmacotherapies for Osteoarthritis with Special Focus on Intra-Articular Treatment.

Authors:  Alicja Nowaczyk; Dawid Szwedowski; Ignacio Dallo; Jacek Nowaczyk
Journal:  Int J Mol Sci       Date:  2022-01-29       Impact factor: 5.923

Review 8.  Aspirin as a potential treatment in sepsis or acute respiratory distress syndrome.

Authors:  Philip Toner; Danny Francis McAuley; Murali Shyamsundar
Journal:  Crit Care       Date:  2015-10-23       Impact factor: 9.097

Review 9.  The Targeting of Nuclear Factor Kappa B by Drugs Adopted for the Prevention and Treatment of Preeclampsia.

Authors:  Agata Sakowicz
Journal:  Int J Mol Sci       Date:  2022-03-07       Impact factor: 5.923

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.